Using LDL to Target Cancer Cells
Author Information
Author(s): AJ Versluis, PJ van Geel, H Oppelaar, TJC van Berkell, MK Bijsterbosch
Primary Institution: Leiden/Amsterdam Center for Drug Research, University of Leiden; The Netherlands Cancer Institute
Hypothesis
Can low-density lipoprotein (LDL) be used as a carrier for selective delivery of anti-neoplastic drugs to tumors?
Conclusion
The study concludes that B16 tumor-bearing mice are a suitable model for evaluating LDL-mediated delivery of cytotoxic drugs to tumors.
Supporting Evidence
- B16 melanoma cells bind LDL with high affinity, indicating potential for drug delivery.
- LDL uptake by B16 tumors was higher than in other tissues, suggesting selective targeting.
- Receptor-mediated uptake of LDL can be regulated by the cholesterol needs of the cells.
Takeaway
This study shows that LDL can help deliver cancer-fighting drugs directly to tumors, which could reduce side effects.
Methodology
The study involved in vitro experiments with B16 melanoma cells and in vivo experiments with C57/BL6 mice to evaluate LDL uptake.
Limitations
The study's findings may not directly translate to human tumors due to differences in LDL receptor expression.
Participant Demographics
Male C57/BL6 mice, 10-15 weeks old.
Want to read the original?
Access the complete publication on the publisher's website